{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:11:40Z","timestamp":1779196300412,"version":"3.51.4"},"reference-count":12,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,10]]},"abstract":"\n Introduction<\/jats:title>\n Immune checkpoint inhibitors, such as programmed death (PD)-1 inhibitor nivolumab, are currently widely used in treatment of various malignancies. Due to their widespread application, any new potential adverse effects due to these agents necessitate careful assessment.<\/jats:p>\n <\/jats:sec>\n \n Case report<\/jats:title>\n We report a case of an 81-year-old man with recurrent high-risk malignant melanoma who underwent a 12-month adjuvant treatment with nivolumab. Shortly after the course of nivolumab, he developed monoclonal B-cell lymphocytosis (MBL) which subsequently progressed to chronic lymphocytic leukemia (CLL).<\/jats:p>\n <\/jats:sec>\n \n Management and outcome<\/jats:title>\n The patient is currently doing clinically well in Rai stage 0. Malignant melanoma remains in remission.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Considering the pathophysiologic plausibility of nivolumab inducing B-cell dysregulation via PD-1 inhibition, we suggest further studies on potential association between nivolumab and B-cell malignancies.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/10781552221074025","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T09:40:03Z","timestamp":1642758003000},"page":"1218-1221","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of Monoclonal B-cell Lymphocytosis Shortly After Treatment with Nivolumab and Subsequent Progression to Chronic Lymphocytic Leukemia"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8488-8312","authenticated-orcid":false,"given":"Arsia","family":"Jamali","sequence":"first","affiliation":[{"name":"Eisenhower Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khashayar","family":"Nemovi","sequence":"additional","affiliation":[{"name":"Eisenhower Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4125-5355","authenticated-orcid":false,"given":"Jaspreet","family":"Kaur","sequence":"additional","affiliation":[{"name":"Eisenhower Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0425-8394","authenticated-orcid":false,"given":"Constantin A","family":"Dasanu","sequence":"additional","affiliation":[{"name":"Eisenhower Health"},{"name":"Department of Medical Oncology and Hematology, University of California in San Diego Health System, San Diego, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1718217115"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0769-3"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000292"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.7150\/jca.17144"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.02.018"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1714"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000247"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.2174\/0929867324666170407125017"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2019.02.009"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxs098"},{"key":"e_1_3_2_13_2","article-title":"Immunosuppressive B cells expressing PD-1\/PD-L1 in solid tumors: a mini review","author":"Sun X","year":"2019","unstructured":"Sun X, Zhang T, Li M, et al. Immunosuppressive B cells expressing PD-1\/PD-L1 in solid tumors: a mini review. QJM : Month J Assoc Phys 2019.","journal-title":"QJM : Month J Assoc Phys"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221074025","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221074025","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221074025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:37:14Z","timestamp":1779194234000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221074025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1177\/10781552221074025"],"URL":"https:\/\/doi.org\/10.1177\/10781552221074025","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]}}}